Table 4 Clinical, functional, exercise tolerance and HRQoL in FILD cases with and without reduced diaphragmatic thickening

Age

54 ± 14^a

47 ± 16^a

Sex, male (%)

5 (55.6%)

13 (61.9)

Body mass index (Kg/m²)

27 ± 3^a

26 ± 4^a

 FVC (% predicted)

69 ± 12^a

53 ± 15^a

 DLCO (%predicted)

48 ± 12^a

40 ± 16^a

MIP (% predicted)

90 ± 22^a

77 ± 25^a

MEP (% predicted)

95 ± 27^a

83 ± 28^a

SNIP (% predicted)

89 ± 5^a

87 ± 12^a

MRC dyspnea scale

2 (1–2.5)^b

3 (2–3.5)^b

 Respiratory symptoms

29.6 (7.7–52.2)^b

42.0 (25.0–57.0)^b

 Activity

37.8 (29.4–60.9)^b

66.3 (38.6–76.3)^b

 Walked distance (m)

516 (405–576)^b

499 (435–552)^b

 Walked distance (%predicted)

93 (84–103)^b

83 (77–94)^b

 Initial SpO₂

96 (93–96)^b

95 (93–96)^b

 Final SpO₂

91 (83–94)^b

85 (68–90)^b

 SpO₂ desaturation at end 6MWT 6MWT

5 (2–10)^b

11 (5–25)^b

 Initial heart rate (ppm)

80 (69–91)^b

84 (70–98)^b

 Final heart rate (ppm)

104 (88–141)^b

119.5 (107–136)

 Initial Borg dyspnea scale

0 (0–1)^b

0 (0–0.3)^b

 Final Borg dyspnea scale

5 (3–5)^b

7 (5–8)^b

 Initial Borg leg fatigue scale

0^b

0^b

 Final Borg leg fatigue scale

3 (1–6)^b

5 (1.5–7)^b